Medicare Part D coverage · posaconazole · RxCUI 2558607
posaconazole 300 MG Powder for Oral Suspension [Noxafil]
Per the CMS 2026 Part D formulary file, posaconazole 300 MG Powder for Oral Suspension [Noxafil] is covered by 122 Medicare Part D plans (2.4% of enrollable products), averaging Tier 4.2, with prior authorization required on 100% of covering formularies.
- 2.4%
- Plan coverage
- 122
- Plans covering
- T4.2
- Avg tier
- 100%
- Prior auth required
What the CMS Formulary Data Shows for posaconazole 300 MG Powder for Oral Suspension [Noxafil]
Per the CMS 2026 Part D formulary file, posaconazole 300 MG Powder for Oral Suspension [Noxafil] (RxNorm concept RXCUI 2558607, generic name posaconazole) appears on 13 distinct formulary files spanning 122 Medicare Part D plan offerings - 2.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.2.
Real-world access to posaconazole 300 MG Powder for Oral Suspension [Noxafil] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 30.8% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 8,353 Part D beneficiaries filled posaconazole 300 MG Powder for Oral Suspension [Noxafil] in 2023, with total plan-and-beneficiary spending of $79,723,895 and an average per-beneficiary annual cost of $9,544.34. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry posaconazole 300 MG Powder for Oral Suspension [Noxafil] today.
Coverage Details
- Formularies covering
- 13
- Plans covering
- 122
- Coverage rate
- 2.4%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 30.8% of formularies
2023 Medicare Spending
- Beneficiaries
- 8,353
- Total spending
- $79,723,895
- Avg per beneficiary
- $9,544.34
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering posaconazole 300 MG Powder for Oral Suspension [Noxafil]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Show the next 30 plans
| Select Health Medicare Wellness (HMO) | Selecthealth, Inc. | T5 | Yes | $0 | NV |
| Alignment Health the ONE + Walgreens (HMO) | Alignment Health Plan OF Arizona, Inc. | T5 | Yes | $0 | AZ |
| Alignment Health the ONE + Walgreens (HMO) | Alignment Health Plan OF Arizona, Inc. | T5 | Yes | $0 | AZ |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan OF Arizona, Inc. | T5 | Yes | $0 | AZ |
| Alignment Health smartHMO (HMO) | Alignment Health Plan OF Arizona, Inc. | T5 | Yes | $0 | AZ |
| Alignment Health My Choice (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Platinum + Instacart (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health AllCare Preferred (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Platinum + Instacart (HMO-POS) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health My Choice (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Harmony (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Balance (HMO C-SNP) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health the ONE (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health the ONE + Walgreens (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health CommUnity (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health smartSavings (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health My Choice Select (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health ValorCare (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health L.A. Premium Giveback (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health S.D. Premium Giveback (HMO) | Alignment Health Plan | T5 | Yes | $0 | CA |
| Alignment Health Platinum (HMO) | Alignment Health Plan OF North Carolina, Inc. | T5 | Yes | $0 | NC |
| Alignment Health NC Duals (HMO-POS D-SNP) | Alignment Health Plan OF North Carolina, Inc. | T5 | Yes | $0 | NC |
Showing top 50 of 100 plans.
Frequently Asked Questions
Is posaconazole 300 MG Powder for Oral Suspension [Noxafil] covered by Medicare Part D?
Yes, posaconazole 300 MG Powder for Oral Suspension [Noxafil] is covered by 122 Medicare Part D plans (2.4% of all Part D formularies).
What tier is posaconazole 300 MG Powder for Oral Suspension [Noxafil] on Medicare Part D plans?
posaconazole 300 MG Powder for Oral Suspension [Noxafil] averages Tier 4.2 across Part D plans, ranging from Tier 1 to Tier 5.
Does posaconazole 300 MG Powder for Oral Suspension [Noxafil] require prior authorization?
100% of Part D formularies require prior authorization for posaconazole 300 MG Powder for Oral Suspension [Noxafil]. Step therapy: 0%. Quantity limits: 30.8%.
How much does Medicare spend on posaconazole 300 MG Powder for Oral Suspension [Noxafil]?
In 2023, total Medicare Part D spending on posaconazole 300 MG Powder for Oral Suspension [Noxafil] was $79,723,895, covering 8,353 beneficiaries. The average spend per beneficiary was $9,544.34.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- amikacin liposomal 70.3 MG/ML Inhalation Suspension [Arikayce] T4.2
- cannabidiol 100 MG/ML Oral Solution [Epidiolex] T4.2
- fecal microbiota spores, live-brpk 30000000 UNT Oral Capsule [Vowst] T4.2
- fenfluramine 2.2 MG/ML Oral Solution [Fintepla] T4.2
- ganaxolone 50 MG/ML Oral Suspension [Ztalmy] T4.2
- ibrutinib 140 MG Oral Capsule [Imbruvica] T4.2
Similar prior-authorization rate
- azathioprine 50 MG Oral Tablet 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Prefilled Syringe [Heplisav-B] 100% PA
- 0.5 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- 1 ML hepatitis B surface antigen vaccine 0.02 MG/ML Prefilled Syringe [Engerix-B] 100% PA
- sotagliflozin 200 MG Oral Tablet [Inpefa] 100% PA
- mycophenolate mofetil 250 MG Oral Capsule 100% PA